Target ALS has launched a new website that offers improved accessibility to patients, researchers, and the ALS community at ...

Columnist Dagmar Munn works to restore good walking posture after recognizing that ALS-related compensations have led to ...

Scientists have developed a computer-based model that may explain how nerve cells become damaged in ALS, and how best to time ...

A study suggests overactive VCP may contribute to ALS nerve damage by disrupting nuclear pore proteins in genetic ALS.

Dewpoint has selected a novel small molecule to prevent the formation of abnormal TDP-43 protein clumps in ALS and other ...

Mindwalk identified TDP-43 antibodies that selectively target abnormal protein clumps linked to ALS and other diseases.

Columnist Kristin Neva recalls a lesson from years ago about not giving in to "what ifs" as she contends with her husband's ...

Faced with stress and brain fog, columnist Juliet Taylor thought that staying on top of things would keep her husband's ALS ...

The first patient has been dosed in a Phase 2 clinical trial testing RAG-17 in people with ALS who carry mutations in the ...

The first healthy volunteers have been dosed in an early clinical trial testing NRG5051, a disease-modifying therapy for ALS ...

The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.

Clene is scheduled to meet with the FDA in the coming months to discuss new data for CNM-Au8, its experimental oral therapy ...